Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1)

OBJECTIVES: Tenapanor is a first-in-class, minimally absorbed, small-molecule inhibitor of the gastrointestinal sodium/hydrogen exchanger isoform 3. This phase 3 trial assessed the efficacy and safety of tenapanor 50 mg b.i.d. for the treatment of patients with constipation-predominant irritable bow...

Descripción completa

Detalles Bibliográficos
Autores principales: Chey, William D., Lembo, Anthony J., Rosenbaum, David P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2020
Materias:
ARTICLE
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771640/
https://www.ncbi.nlm.nih.gov/pubmed/31934897
http://dx.doi.org/10.14309/ajg.0000000000000516

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771640/
https://www.ncbi.nlm.nih.gov/pubmed/31934897
http://dx.doi.org/10.14309/ajg.0000000000000516

Ejemplares similares